Yuhan Corporation (KRX:000100) told the exchange on September 1 that it had taken an order for active pharmaceutical ingredients worth ₩131,074,406,400, which the filing states is USD 95,424,000 converted at ₩1,373.60 to the dollar. It runs from that day to May 31, 2028. The buyer is described only as a global pharmaceutical company. There is no deposit and no advance payment, and the field for supply region says undetermined.
Two details make this smaller than the headline number suggests, and both are in the filing rather than in the coverage. The first is a footnote explaining that the stated contract date is the date the purchase order was received. This is an order under a commercial relationship, not the signing of a multi-year supply agreement, and the filing separately notes the end date can move if both sides agree. The second is that the amount is spread over twenty-one months. Call it ₩75bn a year against ₩2,186.6bn of FY2025 revenue, so about 3.4% annually rather than the 6.0% the filing reports against a single year of sales.
A US investor reading a Korean supply-contract disclosure should know why it's there. Korean exchange rules require a listed company to file a single sale-or-supply contract disclosure (단일판매ㆍ공급계약체결) when the amount crosses a fixed share of recent annual revenue: 5% for companies classified as large corporations, 10% for everyone else. Yuhan's filing marks 대규모법인여부 — whether it is a large corporation — as applicable, and the contract comes in at 6.0%.
That is a bright line, and it works differently from the American equivalent. A US filer decides whether a contract is material under a qualitative standard, files an 8-K if it concludes yes, and negotiates redactions with the SEC if a counterparty objects. In Korea the percentage decides, and the company then applies separately to withhold the terms. Yuhan did that: the disclosure hold (공시유보) is on grounds of business confidentiality at the counterparty's request, expiring May 31, 2028, which is the day the contract ends.
So the useful inference runs backwards. Any sealed Korean supply contract you see filed is at least 5% of the filer's revenue, because otherwise you would never have seen it. And the counterparty's name arrives only after the commercial value of knowing it has gone.
Yuhan is bought internationally as a lazertinib story — the lung-cancer drug it out-licensed to Johnson & Johnson, which sells it in the US paired with its own antibody, generating milestones and royalties. The income statement doesn't look like that at all.
FY2025 revenue was ₩2,186.6bn and operating income was ₩104.4bn. That's a 4.8% operating margin. FY2024 was 2.7%. FY2019 was 0.8%, on ₩1,480.4bn of revenue. Over eleven years the operating margin has never once reached 8%. These are distribution economics, not pharmaceutical economics, and they come from a domestic business built on moving other people's medicines and its own established products through Korean pharmacies and hospitals.
Then look at what happens below that line. FY2025 pretax income was ₩222.7bn against ₩104.4bn of operating income. Finance income was ₩18.8bn and finance costs ₩25.5bn, so those don't close the gap. Roughly ₩125bn of pretax profit came from somewhere the operating line doesn't show. Q4 2025 makes it vivid: ₩26.1bn of operating income, ₩120.9bn of pretax income, ₩110.1bn of net income in a single quarter.
The financial statement lines available to me don't identify what produced it. The two candidates are equity-accounted affiliates and licensing income, and the notes in the half-year report are where that gets settled. What I can say without guessing is that anyone valuing Yuhan on its operating margin is valuing the wrong half of the company, and anyone valuing it on net income is relying on items that arrive in lumps.
Which is what makes a ₩131.1bn ingredient order more interesting than its size. API supply is contract manufacturing: you make a molecule to specification, ship it, and get paid. It doesn't depend on a clinical readout or a partner's launch curve. Twenty-one months of visible orders in that business is worth more per won of revenue, in planning terms, than the same won arriving as an unpredictable milestone.
It also has to be paid for upfront by Yuhan. No deposit, no advance, means the company carries the inventory and manufacturing cost until delivery. That's ordinary in this business, but it shows up: purchases of property, plant and equipment were ₩60.2bn in Q2 alone, against ₩99.6bn for all of FY2025, and inventories rose from ₩372.8bn at December to ₩420.0bn in June.
The recent trend gives the company room to absorb it. Q2 2026 revenue of ₩639.5bn was the highest of the eight quarters in the record, with ₩66.9bn of operating income, a 10.5% margin, against 8.6% a year earlier. First-half revenue of ₩1,166.2bn is up 8.9% and first-half operating income of ₩75.7bn is up 34.5%. Cash was ₩427.9bn at the end of June against total liabilities of ₩859.3bn and equity of ₩2,471.0bn. This is a conservatively financed company.
The order is 2.2% of a ₩6.09tn market capitalisation, spread over almost two years. Even at a healthy gross margin it changes annual operating income by tens of billions of won at most, in a company where a single quarter's non-operating item has swung profit by more than ₩90bn. It's a good order. It is not a repricing event, and the shares closed at ₩82,700 on the day of the filing, down 1.2% from ₩83,700, which is roughly what you'd expect from a market that agreed.
There's a governance-adjacent point too. Between the sealed counterparty, the undetermined supply region, and a contract date that is really an order date, an investor is being asked to accept an amount and two dates. The end date can change by agreement. Nothing here is improper — it's the disclosure regime working as written — but a reader should treat the ₩131.1bn as a ceiling that the parties can revise rather than as contracted revenue.
And the valuation isn't undemanding. At ₩82,700 the shares carry a ₩6.09tn market cap, about 33 times FY2025 net income of ₩185.3bn, 33 times first-half earnings annualised, and 2.46 times the ₩2,471.0bn of equity. The stock is 34% below its ₩125,000 fifty-two-week high, so expectations have already come down, but 33 times earnings for a business with a 5% operating margin is a price that assumes the licensing side keeps delivering.
The Q3 report in November, and specifically whether the API order shows up as a step in revenue or gets lost inside the quarterly noise. On a twenty-one month schedule, roughly ₩19bn a quarter, it will be hard to see, which itself tells you how to size it.
More importantly, the half-year report's notes on non-operating income. That's the document that explains the gap between a 4.8% operating margin and the profit this company actually reports, and it's more decisive for the equity than any single supply order. If the answer is recurring affiliate income, this is a stabler business than the operating line suggests. If it's lumpy licensing, the FY2026 result depends on events with dates nobody has published.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.